| (Values in U.S. Thousands) | Dec, 2016 | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 |
| Sales | -9,999,000 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -12,660 | -16,280 | -13,060 | -11,230 |
| Net Income Growth | -78,881.05% | +22.24% | -24.66% | -16.30% | -25.47% |
Colucid Pharma Cmn (CLCD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company's product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.
Fiscal Year End Date: 12/31